RB1 and prostate cancer: A recent study explored intrapatient molecular heterogeneity in patients with metastatic castration-resistant prostate cancer: these patients displayed a high prevalence of RB1 genomic aberrations, with structural variants, including rearrangements (such as intragenic tandem duplication), being common [67]; RB1 immunohistochemistry showed a heterogeneous expression in 28% of cases [67].